Page last updated: 2024-11-04

lomefloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lomefloxacin is a synthetic fluoroquinolone antibiotic. It is effective against a wide range of gram-positive and gram-negative bacteria. Lomefloxacin inhibits the activity of bacterial DNA gyrase, an enzyme essential for DNA replication. This inhibition leads to bacterial cell death. Lomefloxacin is used to treat a variety of infections, including urinary tract infections, respiratory infections, and skin infections. It is also used to treat gonorrhea and chlamydia. Research on lomefloxacin focuses on its potential efficacy in treating various infectious diseases and exploring its pharmacokinetic properties. Its ability to cross the blood-brain barrier makes it potentially useful in treating central nervous system infections. However, its use is limited due to potential side effects like tendonitis and neurotoxicity.'

lomefloxacin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3948
CHEMBL ID561
CHEBI ID116278
SCHEMBL ID34609
MeSH IDM0150494

Synonyms (112)

Synonym
3-quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-
lomefloxacino [spanish]
lomefloxacinum [latin]
sc 47111a
(+-)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
lomefloxacine [french]
ccris 6305
brn 4210041
3-quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, (+-)-
AB00053622-04
BRD-A75850590-003-05-6
KBIO1_000365
DIVK1C_000365
SPECTRUM_001431
PRESTWICK2_000238
SMP1_000287
NCGC00178293-02
NCGC00178293-01
3-quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- (+/-)
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
dm 10 (bactericide)
sc-47111b (mesylate)
dm-10
sc-47111a
ny-198 (hydrochloride)
sc-47111 (hydrochloride)
maxaquin (hydrochloride)
LOPAC0_000678
PRESTWICK3_000238
BSPBIO_003107
IDI1_000365
SPECTRUM5_001246
BSPBIO_000315
C07078
98079-51-7
lomefloxacin
DB00978
1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
(+/-)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
lomefloxacin (usan)
D02318
lflx
KBIO2_004479
KBIOSS_001911
KBIOGR_000636
KBIO2_007047
KBIO3_002607
KBIO2_001911
SPECTRUM4_000158
PRESTWICK1_000238
SPECTRUM3_001494
NINDS_000365
PRESTWICK0_000238
SPBIO_002236
SPECTRUM2_000696
SPBIO_000851
BPBIO1_000347
NCGC00162221-01
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
lomefloxacine
lomefloxacinum
lomefloxacino
CHEBI:116278 ,
HMS2090O16
NCGC00015603-05
CHEMBL561
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
l6br2wjd8v ,
unii-l6br2wjd8v
lomefloxacin [usan:inn:ban]
1-ethyl-6,8-difluoro-7-(3-methylpiperazinyl)-4-oxohydroquinoline-3-carboxylic acid
CCG-204764
AKOS015964770
NCGC00015603-02
NCGC00015603-03
NCGC00015603-04
bdbm50417952
FT-0601634
NCGC00015603-07
EPITOPE ID:119067
S5491
lomefloxacin [vandf]
lomefloxacin [usan]
lomefloxacin [who-dd]
lomefloxacin [inn]
(+/-)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-
3-quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)-
lomefloxacin [mi]
HY-B0455A
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride
SCHEMBL34609
KS-5014
1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid
AB00053622-05
3-quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-
AB00053622_06
AB00053622_07
DTXSID4040680
STL483414
sc47111a
SBI-0050657.P003
rkl10067
lomefloxacin,(s)
BCP11730
Q203618
BRD-A75850590-003-06-4
SDCCGSBI-0050657.P004
NCGC00015603-16
1-ethyl-6-fluoranyl-8-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
lomefloxacin 1000 microg/ml in acetonitrile
EN300-18553898
gtpl12407

Research Excerpts

Overview

Lomefloxacin (LFX) is a widely used fluoroquinolone antimicrobial agent that plays an important role in the treatment of human and animal infections. It has been reported to cause phototoxicity.

ExcerptReferenceRelevance
"Lomefloxacin is a second-generation difluorinated broad-spectrum quinolone antibiotic. "( Lomefloxacin.
Al-Wabli, RI,
)
3.02
"Lomefloxacin (LFX) is a widely used fluoroquinolone antimicrobial agent that plays an important role in the treatment of human and animal infections; however, it has been reported to cause phototoxicity. "( Photodynamically-induced Apoptosis Due to Ultraviolet A in the Presence of Lomefloxacin in Human Promyelocytic Leukemia Cells.
Imaizumi, T; Iwase, Y; Nakai, S; Nishi, K; Okudaira, K; Watanabe, T; Yumita, N, 2017
)
2.13
"Lomefloxacin is a potent bactericidal antibiotic. "( Cytotoxic effect of lomefloxacin in culture of human epidermal melanocytes.
Beberok, A; Buszman, E; Otręba, M; Wrześniok, D, 2013
)
2.16
"Lomefloxacin is a broad-spectrum fluoroquinolone antibiotic used for the treatment of bacterial extraocular disease. "( Efficacy and safety of lomefloxacin on bacterial extraocular disease in the horse.
Ando, K; Fujii, Y; Hidaka, S; Kobayashi, M, 2015
)
2.17
"Lomefloxacin is a kind of synthetic fluoroquinolone antibiotic, which is used for the treatment of infectious diseases. "( Development of a UPLC-MS/MS method for the determination of lomefloxacin in rabbit aqueous humor and its application to a pharmacokinetic study.
Liu, X; Miao, Q; Song, S; Sun, J; Wang, Y; Xu, M; Zhang, P; Zhao, D; Zhong, L, 2016
)
2.12
"Lomefloxacin is a difluorinated quinolone antibacterial drug. "( Abatement by naringin of lomefloxacin-induced genomic instability in mice.
Attia, SM, 2008
)
2.09
"Lomefloxacin hydrochloride is a third generation fluoroquinolone antibacterial agent having a broad spectrum of action against a wide range of gram-positive and gram-negative organisms. "( In vitro availability of lomefloxacin hydrochloride in presence of essential and trace elements.
Arayne, MS; Furqan, H; Sultana, N, 2005
)
2.07
"Lomefloxacin is a new quinolone compound with a broad antibacterial spectrum and excellent penetration into the aqueous humor by topical application. "( Application of topical lomefloxacin against experimental Pseudomonas endophthalmitis in rabbits.
Hatano, H; Inoue, K; Liping, W; Shia, S, 1993
)
2.04
"Lomefloxacin is a quinolone antibiotic with chemical and microbiological properties similar to most commercially available agents of this class. "( Lomefloxacin clinical pharmacokinetics.
Belliveau, PP; Freeman, CD; Nicolau, DP; Nightingale, CH, 1993
)
3.17
"Lomefloxacin is a new fluoroquinolone with effective broad-spectrum antimicrobial activity. "( The UVR wavelength dependence for lomefloxacin photosensitization of human skin.
Fakouhi, TD; Harrison, GI; Hawk, JL; Roniker, B; Swabb, EA; Young, AR, 1996
)
2.02
"Lomefloxacin is a new fluorine-containing antibiotic that has recently been approved for general use. "( The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies.
DeJesus, OJ; Frank, P; Macy, D; Nickles, RJ; Perlman, SB; Taylor, M; Tewson, TJ; Wong, G; Yang, D, 1996
)
2.03
"Lomefloxacin proved to be a safe and efficient up-to-date agent for the treatment of tuberculosis in patients with hepatitis due to the use of antituberculosis drugs."( [Lomefloxacin in phthisiatric practice].
Grishin, VK; Polunina, TE, 1998
)
1.93
"Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB). "( Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001
)
2.05
"Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation. "( The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Rizk, E, 1992
)
2.01
"Lomefloxacin is a new, difluoroquinolone. "( In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens.
Felmingham, D; Robbins, MJ,
)
1.89
"Lomefloxacin is a new oral fluoroquinolone that is indicated for the treatment of various bacterial infections."( Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Nix, DE; Symonds, WT, 1992
)
2.45
"Lomefloxacin (NY-198) is a chemotherapic agent from the new 4-quinolone group, acting on DNA gyrase system. "( In vitro toxicity of lomefloxacin in rabbit corneal epithelial cell cultures.
Igual, A; Jauch, A; Nos-Barbéra, S; Portolés, M, 1990
)
2.04
"Lomefloxacin is a promising new difluorinated quinolone with good antimicrobial activity and favorable pharmacokinetic properties. "( In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
DiVincenzo, CA; Shatzer, KL; Venezio, FR,
)
1.89
"Lomefloxacin is a new difluoro-quinolone. "( Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
Baskerville, AJ; Felmingham, D; Grüneberg, RN; Mumtaz, G; Ridgway, GL; Robbins, MJ; Sanghrajka, M,
)
1.86

Effects

Lomefloxacin has marked activity against Gram-negative bacilli including Enterobacteriaceae, non-fermenting strains and Haemophilus influenzae. 98% of all isolates tested had MICs of 0.25 mg/l or less.

ExcerptReferenceRelevance
"Lomefloxacin has the economic advantage of an oral route of administration compared to the parenteral route of cefotaxime for prophylaxis in transurethral genitourinary procedures."( Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime.
Berger, NS; Crawford, ED; Davis, MA; Donohue, RE, 1992
)
1.23
"Lomefloxacin has been shown to produce high and sustained concentrations in serum and bronchial mucosa after once-daily administration. "( A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
Kemper, P; Köhler, D, 1992
)
1.98
"Lomefloxacin has only modest activity against common gram-positive organisms."( Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Nix, DE; Symonds, WT, 1992
)
2.45
"Lomefloxacin has marked activity against Gram-negative bacilli including Enterobacteriaceae, non-fermenting strains and Haemophilus influenzae with 98% of all isolates tested having MICs of 0.25 mg/l or less. "( Antibacterial activity of lomefloxacin.
Leigh, DA; Tait, S; Walsh, B, 1991
)
2.02

Actions

ExcerptReferenceRelevance
"Lomefloxacin because of its longer half life and convenient BD dose was used in a multicentre study to treat cases of typhoid group of fevers including cases due to multiresistant isolates."( Typhoid fevers: treatment with lomefloxacin.
Ahmad, N; Habib, F; Hafiz, S; Haq, I; Husain, R, 1998
)
1.31

Treatment

Lomefloxacin pretreated bacteria were more susceptible to killing by PMN than untreated bacteria. Treatment with lomeflOxacin for seven days reduced mortality with a 50% effective dose of 2.5-7.8 mg/kg/day. Lomefloxicin treatment did not alter theophylline clearance.

ExcerptReferenceRelevance
"Two lomefloxacin-treated patients (3%) and four patients treated with ciprofloxacin (5%) withdrew from treatment because of adverse events."( A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.
Cox, CE, 1992
)
1.03
"Lomefloxacin pretreated bacteria were more susceptible to killing by PMN than untreated bacteria."( Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.
McDonald, PJ; Pruul, H, 1990
)
2.44
"Lomefloxacin treatment did not alter theophylline clearance."( Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline.
Atkinson, HC; Begg, EJ; Frampton, CM; Robson, RA; Saunders, DA, 1990
)
1.27
"Treatment with lomefloxacin for seven days reduced mortality with a 50% effective dose of 2.5-7.8 mg/kg/day."( Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin.
Butler, T; Cartagenova, M; Dunn, D, 1990
)
0.85

Toxicity

We studied sparfloxacin (SPFX) and other new quinolone antibiotics. Adverse effects were observed on 20 occasions in 12 patients (one stopped treatment) Treatment-related adverse events were reported for 7% of patients in the lomefloxACin group.

ExcerptReferenceRelevance
" Treatment-related adverse events were reported for 7% of patients in the lomefloxacin group and 5% in the cefaclor group."( Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Ellison, WT; Gotfried, MH, 1992
)
0.83
" Adverse events probably related to treatment occurred in 6% of those treated with lomefloxacin and in 7% of patients treated with TMP/SMX."( Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study.
Aguirre-Avalos, G; Andrade-Villanueva, J; Flores-Gaxiola, A; Lopez-Guillen, P; Morfin-Otero, R; Rodriguez-Noriega, E, 1992
)
0.77
" Two lomefloxacin-treated patients (3%) and four patients treated with ciprofloxacin (5%) withdrew from treatment because of adverse events."( A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.
Cox, CE, 1992
)
1.06
" Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant)."( Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.
Benne, RA; Boon, TA; de Hond, HA; de Wit, MA; Havinga, WH; Hoepelman, IM; van Asbeck, FW; Verhoef, J; Visser, MR; Zwinkels, M, 1993
)
0.9
"To elucidate the mechanism of phototoxicity induced as a side effect by some of the new quinolone antibiotics, we studied sparfloxacin (SPFX), lomefloxacin, enoxacin, ofloxacin, and ciprofloxacin."( Participation of reactive oxygen species in phototoxicity induced by quinolone antibacterial agents.
Arakane, K; Hirobe, M; Mashiko, S; Nagano, T; Ryu, A; Umezawa, N, 1997
)
0.5
"Today's lifestyle is often associated with frequent exposure to sunlight, but some xenobiotics used in drugs, cosmetics or food chemicals can produce adverse biological effects when irradiated."( Fluoroquinolones as chemical tools to define a strategy for photogenotoxicity in vitro assessment.
Agapakis-Causse, C; Belaidi, JP; Chaubo, C; Marrot, L; Meunier, JR; Perez, P, 2001
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The use of this drug in treatment of various infections is accompanied by serious adverse effects on pigmented tissues."( Cytotoxic effect of lomefloxacin in culture of human epidermal melanocytes.
Beberok, A; Buszman, E; Otręba, M; Wrześniok, D, 2013
)
0.71
" One of the 65 horses reported adverse events that had no causal relation with the eye drops."( Efficacy and safety of lomefloxacin on bacterial extraocular disease in the horse.
Ando, K; Fujii, Y; Hidaka, S; Kobayashi, M, 2015
)
0.73
" Adverse events were monitored throughout the study."( Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin.
Cammarata, S; Dawe, RS; Duffy, E; Ferguson, J; Ibbotson, S; Lawrence, L; Paulson, S, 2018
)
0.7
" The main toxic effect of the substances was related to inhibition of mitochondrial dehydrogenases (succinate dehydrogenase and α-glycerol phosphate dehydrogenase) usually followed by suppression of activity of hydrolytic enzymes (acid phosphatase and non-specific esterase)."( Cytochemical Evaluation of the Toxic Effects of Combined Antituberculosis Substances on Metabolic State of Blood Lymphocytes.
Dolgushin, MV, 2020
)
0.56

Pharmacokinetics

The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution and lack of significant metabolism. There are no competitive drug interactions with other metabolised drugs showing a common metabolic pathway. The elimination half-life increased significantly with the degree of renal impairment.

ExcerptReferenceRelevance
"Fluoroquinolones have similar chemical structures but wide differences in their pharmacokinetic profiles."( Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
Blum, RA, 1992
)
0.53
" Compared with the data reported for young adults, the elimination half-life (12."( Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992
)
0.53
" The mean serum half-life on the first day was 10."( The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.
Cowling, P; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; Rogers, S; White, LO, 1991
)
0.59
" For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
" Mean Cmax values (0."( Pharmacokinetics and safety of single oral doses of lomefloxacin.
Morse, IS,
)
0.38
" The results of simulating the antibiotic pharmacokinetic profiles by the Kd values known from the literature and the values estimated with the proposed method were compared."( [Physiologic model of NY-198 pharmacokinetics using a new method of determining tissue/blood distribution coefficient].
Manuĭlov, KK, 1990
)
0.28
" Plasma half-life was approximately 8 hr."( Pharmacokinetics and safety of lomefloxacin following multiple doses.
Adams, MA; Hunt, TL,
)
0.42
"Comparative physiological pharmacokinetic analysis has been carried out to elucidate the different tissue distribution characteristics among eight pyridonecarboxylic acids including newly developed NY-198."( Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids.
Kato, H; Nagata, O; Nakamura, M; Okezaki, E; Terasaki, T; Tsuji, A,
)
0.13
" The mean time to Cmax (Tmax) values averaged 64."( Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.
Kunka, RL; Mant, TG; Morrison, PJ; Norman, GT; Robinson, J, 1988
)
0.55
" None of the pharmacokinetic parameters differed significantly after prior treatment with omeprazole compared with placebo."( Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.
Koeppe, P; Lode, H; Rost, KL; Schaberg, T; Stuht, H, 1995
)
0.61
" It is not clear whether this pharmacokinetic interaction might be clinically important."( Renal clearance of lomefloxacin is decreased by furosemide.
Ebihara, A; Fujimura, A; Harada, K; Ohashi, K; Sasaki, M; Shiga, T; Sudoh, T; Tateishi, T, 1994
)
0.62
" Pharmacokinetic parameters after tablet did not differ significantly from the corresponding values after capsule."( Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers.
Diao, Y; Ji, G; Li, L; Lu, J; Wang, EH; Zhu, XD, 1993
)
0.54
" The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution, lack of significant metabolism (and, therefore, no competitive drug interactions with other metabolised drugs showing a common metabolic pathway), and good oral absorption."( Lomefloxacin clinical pharmacokinetics.
Belliveau, PP; Freeman, CD; Nicolau, DP; Nightingale, CH, 1993
)
1.99
"The area under the plasma concentration-time curve and the elimination half-life of lomefloxacin were significantly increased following coadministration with ranitidine."( Effect of ranitidine on renal clearance of lomefloxacin.
Fujimura, A; Harada, K; Ohmori, M; Sakamoto, K; Sudoh, T; Sunaga, K, 1996
)
0.78

Compound-Compound Interactions

ExcerptReferenceRelevance
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
" The comet tail lengths of epidermal cells of the mice were statistically significantly increased for all three fluoroquinolones (FQ) tested in combination with UV irradiation."( Photo-chemically induced DNA effects in the comet assay with epidermal cells of SKH-1 mice after a single oral administration of different fluoroquinolones and 8-methoxypsoralen in combination with exposure to UVA.
Gross-Tholl, N; Herbold, B; von Keutz, E; Wirnitzer, U, 2006
)
0.33

Bioavailability

Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations. Its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible.

ExcerptReferenceRelevance
" At all dose levels and schedules, lomefloxacin was well absorbed and achieved peak plasma concentrations approximately 1 hour after administration."( Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
Mant, TG, 1992
)
0.84
" Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations and its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible."( Antibacterial activity of lomefloxacin.
Leigh, DA; Tait, S; Walsh, B, 1991
)
1.49
" The bioavailability of tablet was comparable to that of capsule."( Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers.
Diao, Y; Ji, G; Li, L; Lu, J; Wang, EH; Zhu, XD, 1993
)
0.54
"The complexation of the fluoroquinolone antimicrobials is important because it has been implicated in reduced oral bioavailability and reduced antimicrobial activity when the drugs are co-administered with antacids or multi-vitamin preparations containing iron."( Characterization of the complexation of fluoroquinolone antimicrobials with metal ions by nuclear magnetic resonance spectroscopy.
Riley, CM; Ross, DL; Takusagawa, F; Vander Velde, D, 1993
)
0.29
" It is usually administered orally and is well absorbed after oral ingestion."( [Urinary tract infections: risk factors and therapeutic trends].
Astorri, AL; Margariti, PA; Mastromarino, C, 1997
)
0.3
" In ocular kinetic studies, lomefloxacin showed nearly 10 times more ocular bioavailability in aqueous humor as compared to ciprofloxacin."( Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer.
Agarwal, HC; Biswas, NR; Gupta, SK; Gupta, YK; Velpandian, T, 1999
)
0.88
" The method was successfully applied to a bioavailability study with five different ciprofloxacin formulations."( Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection.
Gonçalves, NJ; Maya, MT; Morais, JA; Silva, NB, 2001
)
0.31
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"The aim of this investigation was to identify the impact of physicochemical properties of three fluoroquinolones (second, third, and fourth generation) on bioavailability in relation to the Biopharmaceutics Classification System (BCS) by in silico and in vitro methods."( Physicochemical properties of lomefloxacin, levofloxacin, and moxifloxacin relevant to the biopharmaceutics classification system.
Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, F, 2014
)
0.69
"The current investigation aims to develop and evaluate novel ocular proniosomal gels of lomefloxacin HCl (LXN); in order to improve its ocular bioavailability for the management of bacterial conjunctivitis."( Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl.
Abdelbary, GA; Awad, GE; Basha, M; El-Hashemy, HA; Khalil, RM, 2017
)
0.91
" The formulated niosomes enhanced the ocular bioavailability of LF through increasing transcorneal permeation and localizing drug at site of action."( Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride.
Abdelbary, A; Ali, AM; Khallaf, RA; Salem, HF, 2017
)
0.67
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations. Its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible. It is suggested that a once daily dose of 400 mg lomefloxicin is suitable for the elderly and that no dosage modification is needed.

ExcerptRelevanceReference
" These results attest to the value of the convenience and simplicity of the oral dosing regimen for lomefloxacin."( The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Rizk, E, 1992
)
0.78
" Both total clearance and renal clearance significantly correlate with creatinine clearance for these fluoroquinolones, and creatinine clearance is a useful clinical marker on which to base dosage adjustments."( Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
Blum, RA, 1992
)
0.53
"Six dosage regimens of oral lomefloxacin, a new difluorinated quinolone, were given to healthy volunteer subjects for 7 days in a randomized, placebo-controlled trial to evaluate pharmacokinetics and tolerability and to determine the optimum dosage schedule."( Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
Mant, TG, 1992
)
0.86
" Dosage adjustments should not be necessary in elderly patients with only minor changes in renal function caused by age-related changes in physiology."( Quinolone pharmacokinetics in the elderly.
Goss, TF; Schentag, JJ, 1992
)
0.28
" The pharmacokinetics of lomefloxacin are dependent on renal function, and appropriate dosage adjustment is necessary when creatinine clearance is less than 30 mL/min/1."( Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
Marstein, S; Nilsen, OG; Saltvedt, E; Walstad, RA, 1992
)
0.87
" The results of this study demonstrate that once-daily treatment with 400 mg lomefloxacin is as effective as twice-daily dosing with 400 mg in patients with acute bacterial exacerbations of chronic bronchitis."( A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
Kemper, P; Köhler, D, 1992
)
0.77
"The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, safety, drug interactions, and dosage and administration of lomefloxacin and temafloxacin, two new antimicrobials, are presented."( Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Nix, DE; Symonds, WT, 1992
)
1.92
" Serial plasma and sputum samples and fractional urine samples were obtained over a steady-state dosing interval."( Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
Glerum, JH; Hoepelman, AI; Kovarik, JM; Rozenberg-Arska, M; Sips, PA; Smit, JM; Verhoef, J, 1992
)
0.53
" leprae; temafloxacin and sparfloxacin were the most active, being fully bactericidal at all three dosage schedules."( Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M, 1992
)
0.28
" In conclusion, once-daily oral dosing with lomefloxacin is a safe and efficacious alternative to twice-daily dosing with TMP/SMX in the treatment of uncomplicated urinary tract infections."( Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole.
Capron, MH; Guibert, J, 1992
)
0.81
" It is suggested that a once daily dose of 400 mg lomefloxacin is suitable for the elderly and that no dosage modification is needed in this patient group."( The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.
Cowling, P; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; Rogers, S; White, LO, 1991
)
0.84
" Lomefloxacin offers certain advantages compared with other quinolone antibacterial drugs in that it may be conveniently administered once daily and theophylline dosage adjustment does not appear to be necessary in patients receiving this bronchodilator concomitantly."( Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Goa, KL; Wadworth, AN, 1991
)
2.63
" Some of the more resistant strains of Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa were studied in a dynamic in-vitro model in order to study dosing strategies."( Antimicrobial effects of lomefloxacin in vitro.
Begg, EJ; Boswell, DR; Chambers, ST; Peddie, BA; Robson, RA, 1991
)
0.58
" Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations and its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible."( Antibacterial activity of lomefloxacin.
Leigh, DA; Tait, S; Walsh, B, 1991
)
1.49
" No additional dosage adjustments appear to be necessary for hemodialysis patients."( Pharmacokinetics of lomefloxacin in renally compromised patients.
Blum, RA; Schentag, JJ; Schultz, RW, 1990
)
0.6
"5 microgram/ml were inhibited with both dosing schedules."( Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.
Rustige, C; Wiedemann, B, 1990
)
0.58
" The eradication rate on each observation day was 100% in both dosage groups."( [Epidemiological and therapeutic study on gonorrheal infection--study on NY-198 (lomefloxacin) single administration therapy. Sapporo Clinical Research Group for STD].
Gohro, T; Hayashi, K; Henmi, I; Kato, S; Kumamoto, Y; Sakai, S; Tabata, S; Tanda, H; Tsunekawa, T; Yoshio, H, 1990
)
0.51
" Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
" Dosage adjustments are necessary in uremic patients."( Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.
Fillastre, JP; Humbert, G; Leroy, A, 1990
)
1.72
" Daily dosage of LFLX and PPA was 600 mg and 2000 mg, respectively administered orally divided into 4 doses."( [Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].
Aoki, T; Kanehisa, N; Matsubara, Y; Murata, M; Nitta, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I, 1989
)
0.55
" This dose, interval, and duration of dosing were chosen to be identical to the highest anticipated clinical dose for the longest anticipated clinical duration."( Pharmacokinetics and safety of lomefloxacin following multiple doses.
Adams, MA; Hunt, TL,
)
0.42
" This study suggests that either once-daily or twice-daily dosage of lomefloxacin should be sufficient to treat urinary or systemic infections, respectively, caused by susceptible pathogens."( Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
Andrews, JM; Ashby, JP; Griggs, D; Stone, JW; Wise, R, 1988
)
0.75
" Males were dosed for 71 days before pairing and then until termination, and females were dosed for 15 days before pairing, throughout mating and until Day 7 of gestation."( Reproductive studies of NY-198 in rats. I. Fertility study.
Higgins, C; McAnulty, PA; Tesh, JM; Tesh, SA; Wilby, OK; Willoughby, CR, 1988
)
0.27
" At the highest dosage (300 mg/kg/day), there was a small reduction in maternal weight gain and a transient reduction in food intake during the treatment period."( Reproductive studies of NY-198 in rats. II. Teratology study.
McAnulty, PA; Tesh, JM; Tesh, SA; Wilby, OK; Willoughby, CR, 1988
)
0.27
" There was a slight maternal response at the highest dosage (300 mg/kg/day), including increased salivation after dosing, reduced food intake in the treated period of gestation and increased water intake during the lactation period."( Reproductive studies of NY-198 in rats. III. Perinatal and postnatal study.
Higgins, C; McAnulty, PA; Tesh, JM; Tesh, SA; Wilby, OK; Willoughby, CR, 1988
)
0.27
" This study was designed to evaluate two dosage regimens of a new difluoroquinolone, lomefloxacin, for prevention of postoperative bacteriuria following VLAP."( Lomefloxacin prophylaxis in visual laser ablation of the prostate.
Costa, FJ, 1994
)
1.96
" Both dosage regimens were well tolerated."( Lomefloxacin prophylaxis in visual laser ablation of the prostate.
Costa, FJ, 1994
)
1.73
" There was no clinically significant difference between the two dosage regimens."( Lomefloxacin prophylaxis in visual laser ablation of the prostate.
Costa, FJ, 1994
)
1.73
" Although there were no statistically significant differences between the two LFLX dosage groups for these parameters at either of the evaluation times, the rates for the 300-mg LFLX dose were slightly superior."( [Clinical efficacy of lomefloxacin (100 mg or 300 mg) single-dose therapy in female acute uncomplicated cystitis].
Aoki, M; Hirose, T; Kumamoto, Y; Miyake, M; Sakai, S; Shibuya, A; Shimamura, S; Takatsuka, K; Umehara, T; Yamazaki, K, 1995
)
0.61
" One of five new quinolones was orally administered, before transurethral resection of the prostate, at the dosage of 200 mg three times daily for 3 consecutive days."( Accumulation of new quinolones in the blood of elderly patients.
Abe, Y; Hasuda, A; Morita, M; Nakagawa, H; Suzuki, K,
)
0.13
" There were no differences in the background factors of the patients between the 2 dosage groups."( [A clinical study on lomefloxacin to find appropriate dose levels in the treatment of respiratory tract infections].
Hasegawa, Y; Ichiyama, S; Ikeda, T; Nakanishi, K; Nishiwaki, K; Saka, H; Shimokata, K; Taniguchi, K; Totani, Y; Yamada, Y, 1993
)
0.6
" Dosage adjustments are required in patients with renal dysfunction."( Lomefloxacin clinical pharmacokinetics.
Belliveau, PP; Freeman, CD; Nicolau, DP; Nightingale, CH, 1993
)
1.73
" In addition, dose-response curves were constructed for erythema as measured by a reflectance device."( The UVR wavelength dependence for lomefloxacin photosensitization of human skin.
Fakouhi, TD; Harrison, GI; Hawk, JL; Roniker, B; Swabb, EA; Young, AR, 1996
)
0.57
" Due to automated intermittent dosing and on-line LC analysis, the system operates unattended."( Automated analytical systems for drug development studies. Part IV. A microdialysis system to study the partitioning of lomefloxacin across an erythrocyte membrane in vitro.
Chang, MF; Knaub, SR; Lunte, CE; Riley, CM; Topp, EM, 1995
)
0.5
" This finding may be due to the somewhat lower initial degree of corneal inflammation in this group and suggests that the course of corneal recovery is predominately dependent on the initial degree of infection with both dosage regimens of lomefloxacin capable of eradicating corneal organisms."( Bacterial keratitis therapy in guinea pigs with lomefloxacin by initially high-followed by low-dosage regimen.
Abalain, ML; Colin, J; Jauch, A; Malet, F, 1995
)
0.73
"Multifactor analysis of the lomefloxacin effect on the primary immune response to T-independent bacterial antigen (vaccine EV fraction 1) and to T-dependent cellular antigen (SRBC) in mice was performed with the use of a wide range of the antibiotic concentrations and the dosage time."( [Effect of lomefloxacin on the synthesis of antibodies to vaccine EV fraction I and hemagglutinins].
Iordanova, AI; Navashin, PS; Nikitin, AV; Smolkina, TV, 1996
)
0.98
" Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days."( [A clinical study in the treatment of acute bacterial infections with fleroxacin].
Cui, H; Hou, J; Li, J, 1996
)
0.61
"), treatment factors (daily dosage of LFLX, duration of treatment, total dose, concomitant drugs, and previous medication, etc."( Photosensitivity reactions caused by lomefloxacin hydrochloride: a multicenter survey.
Arata, J; Horio, T; Ohara, K; Soejima, R, 1998
)
0.57
"Lomefloxacin eye drops used with a loading dosage followed by a twice daily regimen proved as effective, safe and well tolerated as five established standard treatments used at a 2, 4 or 5 times daily regimen, caused less discomfort upon instillation, and showed a lower risk to generate or select new resistant strains."( Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis.
Fsadni, M; Gamba, G; Jauch, A, 1999
)
1.99
" This open, cross-sectional, multicenter study has evaluated the efficacy and safety of a once-daily dosage of 400 mg lomefloxacin in patients with AECB chronically treated with theophylline."( Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001
)
0.81
" Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence."( The expanding role of fluoroquinolones.
Schaeffer, AJ, 2002
)
0.31
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
" Animals were killed on Days 2, 3, 4, 5 or 8 (the dosing day was designated as Day 1), and the incidence of micronucleus in the epidermis was determined."( In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice.
Furuhama, K; Itoh, S; Katoh, M, 2002
)
0.31
" The proposed methods could be applied successfully to the investigated pure compounds and pharmaceutical dosage forms with good accuracy and precision."( [Fluorescence spectroscopy determination of lomefloxacin by charge transfer complex formation with chloranilic acid].
Du, LM; Yuan, JM; Zhou, J, 2004
)
0.58
" The dosing of the drugs were scheduled for both treatment groups as follows: 1 drop of each solution was alternately instilled every 5 minutes for the first 30 minutes (as loading dose), then 1 drop with 5-minute interval between 2 bottles instilled hourly for day 1-3, tapering to every 2 hours on day 4-6, and every 4 hours on day 7-14."( Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis.
Erjongmanee, S; Kasetsuwan, N; Pariyakanok, L; Phusitphoykai, N; Puangsricharern, V, 2004
)
0.6
" The method was applied to the determination of LFX, SFX and GFX in dilute urine samples and dosage forms, and compared with the HPLC method."( Electrochemical adsorptive behavior of some fluoroquinolones at carbon paste electrode.
Abdel Ghani, NT; El Ries, MA; El-Shall, MA; Wassel, AA, 2005
)
0.33
" The proposed methods were also applied for the determination of the investigated drugs in their pharmaceutical dosage forms and their validity was assessed using the standard addition technique with mean percentage recovery ranging from 100."( Stability indicating methods for the determination of some fluoroquinolones in the presence of their decarboxylated degrades.
Abd-El-Fattah, Lel-S; El-Guindi, NM; Mikael, HK; Salem, MY, 2006
)
0.33
" It is confirmed that the addition dosage of PVP is an important factor in the preparation of the LFLX-Tb3+ nanoparticles."( [Preparation of lomefloxacin-Tb3+ nanoparticles modified by PVP via microwave-assistance and its properties of fluorescence].
He, H; Liu, X; Ye, HY, 2007
)
0.69
"Intravitreal (ITV) dosing has become a clinically important route of administration for the treatment of uveitis, endophthalmitis, retinal vein occlusion, diabetic macular edema and age-related macular degeneration."( Intravitreal administration of known phototoxicants in the rabbit fails to produce phototoxicity: implications for phototoxicity testing of intravitreally administered small molecule therapeutics.
Baker, JF; Bantseev, V; Brown, MH; Farman, C; Learn, DB; Schuetz, C; Thackaberry, EA, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
photosensitizing agentA chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
antitubercular agentA substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
quinolone
N-arylpiperazine
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.06740.100020.879379.4328AID488772; AID588453; AID588456
EWS/FLI fusion proteinHomo sapiens (human)Potency0.74270.001310.157742.8575AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
flap endonuclease 1Homo sapiens (human)Potency18.88760.133725.412989.1251AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency10.69100.425612.059128.1838AID504536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)2,398.83010.00091.901410.0000AID576612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (392)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID394294Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po measured after 4 hrs of 18 J/cm'2 UV light irradiation2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1653047Antibacterial activity against Staphylococcus aureus2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1480849Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID318935Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 24 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID1279139Permeability of the compound at 25 ug/ml at pH 7.4 after 16 hrs by PAMPA2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1600095Antibacterial activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1183278Permeability of the compound by PAMPA2014European journal of medicinal chemistry, Sep-12, Volume: 84Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID63898Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA26461991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1600146Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 4 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1623120Effective permeability of the compound by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID395097Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID1600127Antibiofilm activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relative to cont2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1585689Antibacterial activity against Klebsiella pneumoniae by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1297667Bacteriostatic activity against Bacillus cereus 8035 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID370641Antibacterial activity against Salmonella Typhimurium after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID367084Antibacterial activity against Staphylococcus aureus after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1478786Permeability of the compound at 200 uL after 16 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
AID1600103Antibacterial activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1653061Antibacterial activity against Vibrio cholerae2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID303476Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID67922Antibacterial activity evaluated against Enterococcus faecalis2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1557304AUC in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1056992Permeability of the compound by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1585686Antibacterial activity against Vibrio cholerae by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1600113Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1557303Cmax in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1297665Bacteriostatic activity against Pseudomonas aeruginosa 9027 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID303474Phototoxicity in UV light irradiated Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID394293Phototoxicity in Swiss albino mouse exposed to 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID316465Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 96 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID303475Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID563513Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 011 harboring plasmid STV28 expressing sdeB gene by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID316457Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 48 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID367087Antibacterial activity against Staphylococcus epidermidis after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID368422Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID52945In vitro antibacterial activity against gram-negative Citrobacter freundii2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID367090Antibacterial activity against Escherichia coli after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID563504Antimicrobial activity against Serratia marcescens ATCC 13880 harboring plasmid STV29 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID205745In vitro antibacterial activity against gram-positive Staphylococcus epidermidis2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID1600130Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID563506Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 harboring plasmid STV29 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID316458Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 72 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID368418Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1392732Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA
AID1378333Permeability of the compound in PBS/EtOH at 100 mg/ml after 16 hrs by PAMPA2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID469403Permeability across PAMPA membrane 2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID316464Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 72 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1297669Bactericidal activity against Bacillus cereus 8035 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID370636Antibacterial activity against Proteus vulgaris after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID394302Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 48 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID325864Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID316459Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 96 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID367085Antibacterial activity against Streptococcus pneumoniae after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID325861Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1890739Permeability of the compound across blood brain barrier incubated for 18 hrs by UV plate reader based PAMPA assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
AID370633Antibacterial activity against Shigella boydii after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID197877Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H2281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID325867Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1279155Permeability of the compound at 25 ug/ml at pH 7.4 after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID367089Antibacterial activity against gamma-streptococcus after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1557305Half life in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1552590Permeability of compound at 25 ug/ml at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
AID436997Inhibition of mouse NIH/3T3 cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID562245Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID370638Antibacterial activity against Morganella morganii after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1297672Bactericidal activity against Pseudomonas aeruginosa 9027 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID1485937Permeability of the compound in PBS/EtOH after 16 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1478796Permeability of the compound by PAMPA-BBB assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
AID1485936Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID562240Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1167550Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
AID1585691Antibacterial activity against Shigella flexneri by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID563505Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 harboring plasmid STV29 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1600099Antibacterial activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID572150Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1295107Permeability of the compound at 100 ug/ml by PAMPA-BBB assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
AID74734MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID303479Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID562244Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID318930Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID1653063Antibacterial activity against Citrobacter freundii2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID394299Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1534778Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID307122Inhibition of HIV1 recombinant integrase strand transfer activity2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID1600114Bactericidal activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID69597Antibacterial activity was evaluated against Escherichia coli2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID325865Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 4 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID563510Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens HMS011 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID198317Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C2031991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID307121Inhibition of HIV1 recombinant integrase 3'-processing activity2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID318932Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID562241Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1534777Effective permeability of the compound at 100 mg/ml incubated for 16 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID1653058Antibacterial activity against Escherichia coli2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID1585690Antibacterial activity against Pseudomonas aeruginosa by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1866897Permeability for across blood brain barrier by PAMPA2022European journal of medicinal chemistry, Apr-15, Volume: 234Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
AID1708807Permeability of compound in PBS/EtOH buffer (70:30) at 25 ug/ml incubated for 16 hrs by UV plate reader based PAMPA-BBB2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1693561Effective permeability of compound in PBS/EtOH buffer (7:3) at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
AID1600105Antibacterial activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1297671Bactericidal activity against Escherichia coli F-50 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1653060Antibacterial activity against Salmonella typhi2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID1347980Permeability of the compound in PBS/EtOH at 100 ug/ml after 12 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1352674Effective permeability at 25 ug/ml after 16 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID563501Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1600096Bactericidal activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID17991Bioavailability2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID307123Antimycobacterial activity against Mycobacterium tuberculosis by agar dilution method2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID1264455Permeability of the compound by high throughput PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID367086Antibacterial activity against Staphylococcus albus after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID325860Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID325866Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 24 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID303480Phototoxicity in UV light irradiated Swiss Albino mouse assessed ear erythema at 140 mg/kg, po2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1413459Permeability of the compound at 50 ug/ml after 16 hrs by PAMPA
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID151052Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-181991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1365650Permeability of the compound at pH 7.4 by BBB-PAMPA2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID1557306Protein binding in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID394298Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 96 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID210380In vitro antibacterial activity against gram-positive Streptococcus pneumoniae2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID1324013Permeability of the compound at 100 ug/ml after 16 hrs by PAMPA-BBB method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1324014Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID394301Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 24 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1495957Effective permeability of the compound in PBS/ethanol buffer after 12 hrs by PAMPA2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID563508Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 harboring plasmid STV29 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID370644Antibacterial activity against Serratia marcescens after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1585687Antibacterial activity against Staphylococcus aureus by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1600100Bactericidal activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID572151Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1480942Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID394300Phototoxicity in Swiss albino mouse assessed as erythema at 140 mg/kg, po after 4 hrs of 18 J/cm'2 UV light irradiation2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1909448Permeability of the compound by PAMPA-BBB assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID436988Inhibition of human HeLa cell proliferation2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID318931Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID563509Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 harboring plasmid STV29 expressing hasF gene by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1636268Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID1585688Antibacterial activity against Staphylococcus epidermidis by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID303484Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 72 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1495958Effective permeability of the compound in PBS/ethanol buffer2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID370635Antibacterial activity against Proteus mirabilis after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID325862Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID427198Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID316454Phototoxic effect in mouse assessed as ear thickness at 140 mg/kg administered before UV light exposure relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1600108Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID368421Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID679038TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 1 uM, LFLX: 10000uM) in bile canalicular membrane vesicles from SD rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID96403In vitro antibacterial activity against gram-negative Klebsiella pneumoniae2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID370639Antibacterial activity against Klebsiella pneumoniae after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID679039TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 1 uM, LFLX: 10000uM) in bile canalicular membrane vesicles from EHBR rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID394296Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 48 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1623078Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1480943Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1600147Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600117Antibacterial activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID325869Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 96 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID368419Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID368424Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID316455Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 4 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1585692Antibacterial activity against Citrobacter freundii by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1653052Antibacterial activity against Shigella flexneri2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID562243Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID206600In vitro antibacterial activity against gram-positive Staphylococcus aureus2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID1600109Antibacterial activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1071344Permeability of the compound by BBB-PAMPA2014European journal of medicinal chemistry, Feb-12, Volume: 731,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID370637Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID562242Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID563512Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 011 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1264447Permeability of the compound by PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID151374Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M17711991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1600126Antibiofilm activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relative to con2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID94001Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID427197Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID370642Antibacterial activity against Citrobacter freundii after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1173449Effective permeability of the compound by PAMPA assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID1392733Permeability of the compound at 100 ug/ml after 10 hrs by PAMPA
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID394297Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 72 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID318936Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID1365649Permeability of the compound at 100 mg/ml after 16 hrs by BBB-PAMPA method2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1585684Antibacterial activity against Salmonella typhi by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1600118Bactericidal activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID394295Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 24 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1705959Effective permeability of compound at 100 ug/ml incubated for 20 hrs by PAMPA-BBB assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
AID303478Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1190185Permeability of the compound after 16 hrs by PAMPA2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID1056993Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID370643Antibacterial activity against Aeromonas hydrophila after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1319976Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID368423Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID316460Phototoxic effect in mouse assessed as number of mouse bearing erythema at 140 mg/kg administered before UV light exposure relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID316461Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 4 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID316463Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 48 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1297666Bacteriostatic activity against Escherichia coli F-50 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID318929Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID367363Antibacterial activity against Shigella sonnei after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID718840Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 after 24 hrs by agar dilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antibacterial activity of new fluoroquinolones containing a cis- or trans-cyclohexane moiety.
AID639368Permeability of the compound by PAMPA assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID427196Membrane permeability by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1600149Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 4 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID206728Antibacterial activity was evaluated against Staphylococcus aureus2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID1653051Antibacterial activity against Klebsiella pneumoniae2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID198176Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-11991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID303477Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID718841Antibacterial activity against Escherichia coli CMCC 44103 after 24 hrs by agar dilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antibacterial activity of new fluoroquinolones containing a cis- or trans-cyclohexane moiety.
AID1600128Antibiofilm activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 0.5 times antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relat2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600104Bactericidal activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID563511Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens HMS011 harboring plasmid STV28 expressing sdeB gene by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1600112Bactericidal activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID307119Cytotoxicity against CEM cells after 5 days by MTT method2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID1533612Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID563507Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 harboring plasmid STV29 expressing hasF gene by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID318934Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 4 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID563503Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID367088Antibacterial activity against Enterococcus faecalis after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1297668Bacteriostatic activity against Staphylococcus aureus 209p measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID682307TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, LFLX: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID57388Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1600111Antibacterial activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID64251Antibacterial activity was determined against gram negative organism, Escherichia coli vogel1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1653062Antibacterial activity against Staphylococcus epidermidis2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID368420Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID164231Antibacterial activity was evaluated against Pseudomonas aeruginosa2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID572147Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1694879Permeability of compound after 16 hrs by PAMPA-BBB assay2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID1600129Antibiofilm activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 0.5 times antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relati2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID563502Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1600148Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 2 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID394303Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 72 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID318937Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID316456Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 24 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1600097Antibacterial activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID394304Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 96 hrs2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.
AID1319973Permeability of the compound by PAMPA assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1402093Antibacterial activity against Staphylococcus aureus2018European journal of medicinal chemistry, Jan-01, Volume: 1434-Quinolone derivatives and their activities against Gram positive pathogens.
AID318938Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 96 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID303482Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 24 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1383661Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
AID318933Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
AID1917372Permeability of compound by PAMPA-BBB assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID370634Antibacterial activity against Shigella flexneri after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID1600116Bactericidal activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID203042In vitro antibacterial activity against gram-negative Shigella boydii2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID1585685Antibacterial activity against Escherichia coli by agar dilution method2019European journal of medicinal chemistry, Jan-15, Volume: 162Fluoroquinolone-isatin hybrids and their biological activities.
AID1653059Antibacterial activity against Pseudomonas aeruginosa2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID1413458Permeability of the compound by PAMPA
AID370640Antibacterial activity against Salmonella enteritidis after 24 hrs by agar dilution method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID74723MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1161578Permeability of the compound by PAMPA-BBB assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID1378334Permeability of the compound by PAMPA2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1347981Permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1600094Lipophilicity, log k of the compound at 100 ug/ml by micellar electrokinetic chromatography2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600106Bactericidal activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID200234Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC761991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID307118Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID316462Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 24 hrs relative to control2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1511118Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1600115Antibacterial activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600098Bactericidal activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600107Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1352675Effective permeability at 25 ug/ml after 18 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID325868Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID1297670Bactericidal activity against Staphylococcus aureus 209p incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID303483Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 48 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID325863Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
AID718842Antibacterial activity against Staphylococcus aureus CMCC 26003 after 24 hrs by agar dilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antibacterial activity of new fluoroquinolones containing a cis- or trans-cyclohexane moiety.
AID1600101Antibacterial activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1753998Permeability of the compound in PBS/EtOH buffer (7:3) incubated for 16 hrs by UV plate reader based PAMPA-BBB assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID303485Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 96 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID1297673Hemolytic activity against human RBC at 0.19 to 3.9 mg/L after 1 hr relative to control2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID198021Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1511119Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1533611Effective permeability of the compound by PAMPA2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID1600145Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 2 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID303481Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 4 hrs of irradiation2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1600110Bactericidal activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID563500Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1198140Permeability of the compound in PBS and EtOH by PAMPA method2015European journal of medicinal chemistry, Mar-26, Volume: 93Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
AID1600102Bactericidal activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (562)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (9.25)18.7374
1990's235 (41.81)18.2507
2000's129 (22.95)29.6817
2010's113 (20.11)24.3611
2020's33 (5.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.75 (24.57)
Research Supply Index6.56 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index74.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials83 (13.39%)5.53%
Reviews30 (4.84%)6.00%
Case Studies13 (2.10%)4.05%
Observational0 (0.00%)0.25%
Other494 (79.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]